Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials
{{output}}
Identification of the optimal dose presents a major challenge in drug development with molecularly targeted agents, immunotherapy, as well as chimeric antigen receptor T-cell treatments. By casting dose finding as a Bayesian model selection problem, we propose... ...
